Relationship between Epstein‐Barr virus (EBV) DNA and the EBV‐determined nuclear antigen (EBNA) in Burkitt lymphoma biopsies and other lymphoproliferative malignancies
Relationship between Epstein‐Barr virus (EBV) DNA and the EBV‐determined nuclear antigen (EBNA) in Burkitt lymphoma biopsies and other lymphoproliferative malignancies
复制标题
伯基特淋巴瘤活检和其他淋巴增殖性恶性肿瘤中 Epstein-Barr 病毒 (EBV) DNA 与 EBV 确定的核抗原 (EBNA) 之间的关系
DOI：
--
复制
发表时间：
1974
影响因子：
6.4
通讯作者：
Surjit Singh
中科院分区：
文献类型：
--
作者：
T. Lindahl;G. Klein;B. Reedman;B. Johansson;Surjit Singh
经组织学确诊的27例非洲Burkitt淋巴瘤中，有26例含有相对大量的EBV DNA(每个细胞10-101个病毒基因组)，这是通过核酸杂交确定的。在26例EBV DNA阳性的淋巴瘤中，有25例在大多数细胞核中含有EBV确定的核抗原EBNA。技术原因可能是一例EBVDNA阳性活检的EBNA明显阴性的原因。四份非洲淋巴瘤活检组织，其中一份确诊为伯基特淋巴瘤，三份同样疾病的诊断有问题，均为EBVDNA和EBNA阴性。瑞典的霍奇金氏病、淋巴细胞性淋巴瘤、慢性淋巴性白血病和其他一些淋巴增殖性恶性肿瘤的病例也是如此。因此，在肿瘤活检中EBV DNA的存在与EBNA的存在之间有很好的一致性。因此，EBNA抗原测试似乎是一种相对简单的检测病毒基因组存在的方法，只要它是在适当的对照下进行的。几例EBV基因组和EBNA阴性病例来自血清EBV抗体滴度较高的患者。结论是，在血清阳性的患者中，病毒并不是真的伴随着恶性淋巴瘤一起传播。与其他淋巴瘤相比，高度流行地区的非洲Burkitt淋巴瘤是独一无二的，因为肿瘤(极少数例外)代表了携带EBV基因组的克隆的增殖。这些发现强调了区分EBV血清阳性状态和EBV基因组携带肿瘤细胞证据的必要性。
Twenty‐six of 27 African Burkitt lymphomas with histologically confirmed diagnosis contained relatively large amounts of EBV DNA (10–101 viral genomes per cell), as determined by nucleic acid hybridization. Twenty‐five of the 26 EBV DNA‐positive lymphomas contained the EBV‐determined nuclear antigen, EBNA, in the majority of the nuclei. Technical reasons may have accounted for the apparent EBNA‐negativity of one EBV DNA‐positive biopsy. Four African lymphoma biopsies, one with a definite diagnosis of Burkitt's lymphoma and three with a questionable diagnosis of the same disease, were all EBV DNA‐ and EBNA‐negative. The same was true for a collection of Swedish cases of Hodgkin's disease, lymphocytic lymphoma, chronic lymphatic leukemia and some other lymphoproliferative malignancies. Thus, there is excellent agreement between the presence of EBV DNA and of EBNA in tumor biopsies. The EBNA antigen test therefore appears a relatively simple way of testing for the presence of the virus genome, provided it is carried out with appropriate controls. Several of the EBV‐genome and EBNA‐negative cases came from patients with high serum titers of EBV antibodies. It is concluded that the virus does not really travel along with malignant lymphomas as a passenger in the seropositive patients. In comparison with other lymphomas, African Burkitt's lymphoma of the high endemic areas is unique in that the tumors (with rare exceptions) represent the proliferation of an EBV‐genome carrying clone. These findings stress the necessity to distinguish between EBV‐seropositive status and evidence for EBV‐genome‐carrying neoplastic cells.